Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromfenac vs Loteprednol for Post-Injection Pain
NCT07090044Phase 4Completed
- Sponsor
- Retina Research Institute
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of bromfenac sodium, loteprednol etabonate ophthalmic gel 0.38% in postprocedural pain (CPSP), sponsored by Retina Research Institute. Started Aug 2021; status: completed.
02
Drugs
bromfenac sodiumloteprednol etabonate ophthalmic gel 0.38%
03
Conditions
postprocedural pain (CPSP)
Beyond the preview
Go deeper on NCT07090044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090044.